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Background: Women who undergo radiotherapy for gynaecological cancer (GC) can experience distressing side effects
which impact on psychosocial functioning and intimate relationships. Cancer-related distress may be ameliorated by
comprehensive preparation for treatment and addressing women’s informational, physical, psychological and
psychosexual needs. This paper describes the protocol for a multisite randomised controlled trial (RCT) testing a novel
intervention package which combines tailored specialist nursing consultations and telephone peer support with the
primary aim to reduce psychological distress. Secondary aims assess patient quality of life, symptom distress, unmet
supportive care needs, preparation for treatment, psychosexual functioning and vaginal stenosis.
Methods/design: This multifaceted intervention comprises four nurse-led consultations coupled with four phone calls
from a peer support volunteer (GC survivor). The evidence-based intervention will be delivered at critical points in the
illness trajectory: pre-treatment, mid-treatment, treatment completion and post-treatment. Nurses and peers undergo
2-day intensive training workshops, are guided by comprehensive study intervention manuals and receive ongoing
supervision and support. Eligible patients will have a diagnosis of GC, be scheduled to receive curative radiotherapy, be
aged 18 years or over and speak English. Three-hundred and six participants will be randomized to receive usual care or
usual care with the intervention package. Study outcome measures will be collected at baseline, day 1 of radiotherapy
and 1, 6 and 12 months post radiotherapy. Clinical assessments of vaginal toxicity will occur at baseline, and 3, 6, and 12
months post radiotherapy.
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Discussion: This timely research has the potential to substantially reduce the physical, psychosexual and supportive care
needs of women with GC. Using a telephone peer support model, the intervention package ensures equitable access to
support services for geographically isolated patients. The novel intervention engages peer volunteers who liaise with
nurses to encourage adherence to professionally-delivered information and provide emotional support. It has been
designed to be potentially transferable to a range of treatment settings and diseases. Based on pilot data, the proposed
intervention was found to be useful and acceptable to patients and clinicians. If effective and feasible in the multisite RCT,
the program could be widely disseminated.
Trial registration: Australian New Zealand Clinical Trial Registry ACTRN12611000744954
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Psychosexual functionBackground
Physical and psychological burden of disease
Gynaecological cancers (GC) account for 19% of all female
cancers worldwide [1], and in addition to the psychological
implications of living with cancer, women with GC experi-
ence significant psychosexual and psychosocial issues
unique to their diagnosis [2,3]. A common treatment for
GC is radiotherapy, which can cause many distressing side
effects that have both immediate and late impacts on qual-
ity of life (QoL) [4]. These side effects include diarrhoea [5],
abdominal cramps [5], bladder dysfunction [6], menopause,
infertility [6] and sexual dysfunction [6]. Women may also
experience vaginal side effects including stenosis, atrophy,
agglutination, reduced genital sensation, vaginal dryness,
dyspareunia and postcoital bleeding [2,7]. As these side
effects involve intimate and private aspects of bodily func-
tion their presence also has a major impact on close rela-
tionships and social functioning.
Not surprisingly, upwards of 40% of GC patients report
chronic and distressing sexual difficulties [2], which may
continue over the 12 months post treatment [8]. GC diag-
nosis also commonly impacts upon a woman’s self-esteem,
body image, femininity and intimate relationships [2,3].
Yet up to half of GC patients report not having any dis-
cussions with their clinicians about post-treatment sexual
adjustment [8,9], which represents a concerning gap in the
provision of healthcare.
In addition to the physical impact, over half of patients
with cancer feel anxious prior to treatment and about
40% remain anxious at treatment completion [3]. High
anxiety has been associated with poorer sexual function-
ing [8], worse QoL up to 1 year post treatment [10] and
lower social support among women with GC [11]. How-
ever, anxiety levels may be ameliorated by both compre-
hensive preparation for treatment and addressing needs
during treatment [12,13].
A Cochrane review published in 2008 recommends
women use a vaginal dilator and/or engage in regular sexual
intercourse [7] to minimise vaginal stenosis and agglutin-
ation after pelvic radiotherapy for GC. Patient adherence tosuch strategies is associated with less physical damage and
greater sexual satisfaction [7,14], and allows adequate pelvic
examination to detect cancer recurrence [15]. However, ad-
herence is suboptimal [7,8]. Moreover, a more recent
Cochrane review generated debate over the appropriate
use of dilators by concluding that there was insufficient
data to recommend routine use [16]. While recommended
practice varies across treatment centres [15], current prac-
tice guidelines internationally advocate the use of a vaginal
dilator for women receiving pelvic radiotherapy [17-20].
Innovative, evidence-based model of supportive care
Given the physical and psychological impact of GC, there
is a high need to provide appropriate and timely interven-
tions to women with these cancers. An evidence-based
intervention combining nurse-led consultations with peer
telephone support has the potential to address these
needs.
Level 1 evidence shows that providing sensory and pro-
cedural information, and addressing patients’ fears about
surgery results in less pain, distress and fewer days in hos-
pital [12,13]. Only two studies have applied these princi-
ples to the radiotherapy context; one found provision of
sensory and procedural information about radiotherapy
resulted in reduced anxiety [21]; the other, a RCT involv-
ing taped procedural and coping information, resulted in
increased perceived knowledge and self-efficacy [22]. This
high level evidence has been incorporated into the study
design as a radiotherapy area tour.
A systematic review showed that there are effective,
evidence-based self-care strategies for side effects common
to several cancer treatments such as fatigue, diarrhoea and
infertility [23]. In addition, involving patients with chronic
disease in their disease management results in improved
self-reported health and lower psychological distress, less
health system use and reduced health costs [24,25]. It is
therefore likely that women treated for GC with radiother-
apy would benefit from a coordinated provision of indivi-
dualised, evidence-based interventions and resources to
optimise their recovery.
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for cancer patients have been shown to be appropriate
and effective [26]. Of interest, health professional deliv-
ery of tailored information to women with GC about
side effects and effective self-care has been linked to
better coping with side effects; compliance with post-
radiation rehabilitation; less fear about sexual inter-
course and less relationship disruption [14,27]. In
addition, evidence from a RCT shows that nurse coordi-
nated multidisciplinary and community referrals result
in better symptom control for cancer patients [28].
Aranda and colleagues have recently demonstrated that
a nurse-led pre-chemotherapy educational consultation
was effective in reducing pre-treatment anxiety amongst
those experiencing moderate to high anxiety at baseline
[29]. As such, individualised and targeted nursing
consultations with provision of evidence-based self-care
strategies are an integral component of the intervention
design.
Multidisciplinary care (MDC) refers to a team ap-
proach to healthcare delivery that involves input from all
relevant medical, nursing and allied health areas. MDC
has been linked to a number of improvements in disease
outcomes, including survival benefits and better QoL,
lower distress, decreased length of hospital stay, reduc-
tion in healthcare costs, improved staff satisfaction and
improved knowledge of patient care [3,27,30]. No studies
testing a system to facilitate MDC for women with GC
have been identified. Effective referral requires that clini-
cians have excellent communication skills to elicit and
respond to patient emotional and information cues. A
systematic review showed that communication skills
training programs improve clinicians’ skills and confi-
dence in psychological assessment and interviewing [31].
The intervention includes training of study nurses to fa-
cilitate appropriate, timely and effective MDC referrals.
In addition to nursing interventions, models of psy-
chosocial cancer care have identified a pivotal role for
peer-support programs [32]. The unique perspective of a
peer facilitates sharing and practical, social and emo-
tional coping [33,34]. A systematic review of cancer
peer-support programs indicated high satisfaction
and perceived psychosocial benefits among participants
[33]. Some patients even prefer peer-delivered over
professionally-delivered support [35]. Telephone models
of peer support have additional economic and logistic
advantages, and are successful in reaching housebound
or geographically isolated patients [36].
Despite widespread use and positive participant per-
ceptions [33], only two RCTs testing one-to-one tele-
phone peer support have been identified in the cancer
literature [37,38]. Rudy and colleagues found that per-
ceived social support was higher among melanoma
patients receiving telephone peer support [38]. Thesecond study reported no significant difference in newly
diagnosed GC patient’s emotional distress with peer tele-
phone support, however the sample size was small
(n=32) [37]. No RCTs investigating peer-support inter-
ventions from treatment initiation to post-treatment
completion were identified [33,35], and none have been
found that combine tailored nurse consultations with
telephone peer support.
This study will evaluate the effect of an innovative,
nurse-led intervention combined with telephone-based
peer support to provide evidence-based information and
resources, coaching in self-care, multidisciplinary refer-
rals and psychological support to optimise the recovery
of women treated for GC with radiotherapy.
Study aims
The primary aim is to evaluate the effectiveness of the
intervention package to reduce psychological distress for
women receiving radiotherapy with curative intent for
GC. Secondary aims are to examine the impact of the
intervention on patient quality of life, symptom distress,
unmet supportive care needs, preparation for treatment,
psychosexual functioning and vaginal stenosis.
Study hypotheses
Primary endpoint
Compared to the usual care group, the intervention
group will report lower psychological distress from base-
line to first follow-up immediately prior to the first
radiotherapy treatment, and follow-up at 4 weeks post
treatment.
Secondary endpoints
Compared to the usual care group, the intervention
group will report:
1. Lower informational and psychosocial supportive
care needs and lower symptom distress from baseline
to follow-up at 4 weeks post treatment,
2. Better preparation for treatment from first follow-up
immediately prior to the first radiotherapy treatment
to follow-up at 4 weeks post treatment,
3. Higher psychosexual functioning from baseline to
follow-up at 6 and 12 months post treatment,
4. Higher quality of life from baseline to follow-up at 4
weeks post treatment, and
5. Less vaginal stenosis at 3, 6 and 12 months post
treatment.
Methods
Design and setting
The trial takes place in six sites from three states of
Australia. All sites are public hospitals, with two sites
part of a specialist oncology facility. The volume of
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contribute equally to participant recruitment.
Ethical approval has been obtained from the Human
Research Ethics Committees of participating states (Peter
MacCallum Cancer Centre Ethics Committee, Project No:
09/07; Ethics Review Committee Royal Prince Alfred
Zone, Project No: X11-0112 & HREC/11/RPAH/154;
Royal Brisbane & Women’s Hospital Human Research
Ethics Committee, Ref No: HREC/11/QRBW/202).
This study is a multicentre, prospective, randomised
controlled intervention trial for patients receiving radio-
therapy for gynaecological cancer, with follow-up of 1
year post-end of treatment.
Participants
Patients will be consecutively screened for eligibility at
participating sites. Inclusion criteria are: (1) have a con-
firmed diagnosis of gynaecological cancer; (2) be sched-
uled to receive radiotherapy with curative intent to the
pelvis; (3) be aged 18 years or older; and (4) be able to
read and write English, and give informed consent. Ex-
clusion criteria are: (1) a severe psychiatric or cognitive
disorder; (2) treatment with palliative intent; or (3) pre-
vious treatment with radiotherapy to any part of the
body.
Patient eligibility will be confirmed by the treating
clinician and the trained data manager will provide add-
itional information and gain written informed consent.
Prior to radiotherapy commencement, the treating clin-
ician will complete a vaginal examination and document
baseline vaginal toxicity. The data manager will be re-
sponsible for liaising with the trained nurses and peers
to organise and coordinate intervention delivery.
Intervention
The psychosocial intervention will involve two linked
components: (1) nurse-led consultations; and (2) peer
telephone support. These elements will be delivered at
four critical points in the illness trajectory: pre-treat-
ment, mid-treatment, treatment completion and post-
treatment. Figure 1 provides a schematic diagram of the
intervention components.
Nurse-led consultations
Training Two specialist cancer nurses will be trained to
provide the consultations at each site. The intervention
nurse will not be involved in the management of ‘usual
care’ patients in order to prevent diffusion of the inter-
vention. Training will comprise online education in dis-
tress management, aspects of survivorship and modules
on the psychosexual care of women with GC. Training
also includes a 2-day workshop facilitated by experts in
communication, cancer nursing, patient education andcoaching, and psychosexual rehabilitation. The work-
shop learning objectives are to: (1) gain an understand-
ing of the project including preventing intervention
diffusion; (2) develop skills to elicit, explore and respond
to patient concerns; and (3) coach and communicate
effectively with patients on the use of evidence-based
self-care strategies and psychosexual issues. Specific
strategies include pelvic floor exercises and the use of
vaginal dilators and moisturisers. Training methods
included didactic and interactive teaching, rehearsal of
skills and constructive feedback using role-plays with
actor-patients and the provision of a detailed intervention
manual.
Intervention session 1: pre-treatment, face-to-face, 1
hour Patients with cancer often report increased unmet
needs related to the worries and fears of family members
[39], so women will be encouraged to bring a significant
other to the consultation. Given that anxiety related to
treatment is typically highest just prior to starting treat-
ment [3] and based on Level I evidence on treatment
preparation [12,13] each patient will be given a brief tour
of the treatment unit followed by a private consultation.
The nurse will first ascertain the patient’s understanding
of their situation and clarify misconceptions. A radio-
therapy question prompt sheet developed from the lit-
erature and with consumer and professional input will
be administered by the nurse and at the first three ses-
sions to guide tailoring of the intervention. The patient
identifies her top three concerns for focus in the session,
with further concerns addressed at future sessions. The
prompt sheet also assesses global distress using the
Distress Thermometer [40]. Anxious patients will be
trained to use the strategy of controlled breathing with
positive self-talk, an effective self-care activity to reduce
treatment-related anxiety [41]. The prompt sheet will aid a
discussion of the woman’s supportive care needs and pos-
sible MDC referrals. The nurse will discuss vaginal health,
psychosexual rehabilitation, and if appropriate, menopause
and infertility. Coaching and rehearsal of self-care for side
effects and stress-reduction will be offered, and tailored
fact-sheets and information provided which can improve
recall [30]. At the end of each session the nurse arranges a
time for a call with the peer volunteer. The nurse also
confirms any particular concerns the patient does not wish
to discuss with her peer.
Intervention session 2: mid-treatment, face-to-face,
30 minutes Since side effects of radiotherapy commonly
commence at 2 to 4 weeks into treatment [17], this ses-
sion addresses side effects and coaching in self-care
strategies. The woman will be provided with lubricants,
informed about and shown how to use the dilator
and perform pelvic floor exercises. The timing of
Figure 1 PeNTAGOn study design: a randomised controlled trial. Schematic diagram of the PeNTAGOn study design. Patients will be
screened for eligibility (criteria listed), then approached and randomised to receive usual care or usual care with the nurse and telephone peer
support intervention. Critical intervention time-points are highlighted pre-, mid-, end- and post-treatment. Time-points for follow-up data
collection to 12 months post end of radiotherapy are noted. Estimates for sample recruitment and retention are shown in each step of the
diagram. Box 1 describes baseline data collected. Box 2 describes key features of the intervention. Boxes 3 to 7 describe follow-up data collection.
AQ, Adherence questionnaire; CaTS, Cancer Treatment Survey; FACT-G, Functional Assessment for Cancer Therapy - General; GC, Gynaecological
cancer; HADS, Hospital Anxiety and Depression Scale; LENT SOMA, Late Effects of Normal Tissues / Subjective-Objective Management Analytic;
MSAS-SF, Memorial Symptom Assessment Scale Short Form; RT, Radiotherapy; SCNS-SF, Supportive Care Needs Survey - Short Form; SVQ, Sexual
function-vaginal changes questionnaire.
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pital policy. In addition, the nurse will assess the
patient’s experience of treatment, normalise fears and
ask about the call with her peer. The nurse will address
any ongoing issues from the first session and new con-
cerns and provide coaching in relevant self-care. Barriers
to self-care and stress-reduction strategies will be eli-
cited and the importance of adherence reinforced [42].Intervention session 3: end of treatment, face-to-face,
30 minutes Some patients report relief upon completing
treatment however research by Jefford et al. has shown
that this is often a time of uncertainty and anxiety [43].
This may be compounded by treatment side effects, both
acute and long-term [2,5,6,14]. In this session the
woman can discuss anxieties related to treatment com-
pletion, ongoing issues and treatment side effects with
the nurse. Vaginal health and psychosexual recovery will
be explored, including the resumption of sexual activity
if desired. The nurse will provide the patient with a
Survivorship Care Plan (SCP) detailing the woman’s
diagnosis and treatment received, planned follow-up
schedule, common ongoing or new treatment side
effects, and how to manage them. With the patient’s per-
mission, the nurse will fax a copy of the SCP to the
patient’s primary care doctor.Intervention session 4: 2 weeks post-treatment, tele-
phone, 30 minutes Many people report feeling aban-
doned and isolated after leaving the hospital system and
an expectation by family and friends to return to ‘normal’
[43]. The nurse will explore concerns and experiences
since completing treatment, address barriers to using self-
care strategies and reinforce the importance of vaginal di-
lator use. The nurse will elicit new or remaining concerns
and respond accordingly before prompting for any final
questions.
Telephone peer support
Each woman will be linked with a peer who will provide
four telephone support sessions throughout the treat-
ment course. Peers will be matched to the participant’s
medical and personal circumstances such as diagnosis,
treatment type, age and area of residence. Approximately
30 peers will be trained over the course of the trial,
accounting for peers taking breaks or withdrawing from
the study. Each peer will support a maximum of two
patients at any one time.
Training Careful selection and training of peers and on-
going professional supervision is critical for the success of
peer support programs [34]. The shortcomings of previouspeer support studies, particularly regarding inadequate
reporting of peer recruitment, training and support, will
be overcome through a rigorous multistage selection and
training process, the provision of ongoing training, super-
vision and debriefing by an experienced cancer nurse, and
provision of a detailed intervention manual [44]. Peers will
be past GC patients identified by clinical staff at participat-
ing centres and sent an invitation letter about the pro-
gram. Peers must be over 18 years old, speak English and
be at least 2 years post treatment. Those with cancer
recurrence or a history of major psychiatric illness are
ineligible. Experts in assessing peer volunteers for phone-
based cancer peer-support programs will conduct screen-
ing phone interviews with interested peers. Suitable
women attend a 2-day workshop. The workshop learning
objectives are to: (1) gain an understanding of the project
including privacy and confidentiality; (2) develop skills in
active listening and providing empathy; and (3) reinforce
self-care strategies recommended by the nurse. In subse-
quent weeks, they complete practice calls with an actor-
patient to apply these skills, and feedback is provided by a
communication skills expert.
Peer intervention sessions The peer will contact the
patient 1 week after each nurse consultation except for
the last session when the peer calls the patient 4 weeks
post treatment. The nurse will call the peer after their
consultation with the patient, and send a check-list of
the patient’s concerns and the individualised self-care
plan. Using a structured format, the peer’s role will be
to:
(1) Provide psychosocial support to the patient: Using
open questions, empathy and active listening, the
peer will establish rapport with the patient, hear her
story and experiences and normalize the woman’s
emotional reaction.
(2) Encourage adherence to the recommended self-care
strategies: The peer will be trained to reinforce
information and coaching on basic self-care
strategies recommended by the nurse, including
problem solving difficulties. For more complex
problems or additional needs, the peer will
encourage the patient to contact the nurse or access
additional sources of information and support, such
as the Cancer Council Helpline. If the peer has
concerns about the patient, she will contact the
nurse and discuss them.
Sample size
The treatment effect is conservatively estimated to result
in group differences of 0.35 standard deviations for con-
tinuous outcome measures [45-47]. With the Hospital
Anxiety and Depression Scale total score (HADS-T) as
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nificance level, the required sample size in each arm is 130
at the 12-month follow-up. With a patient approach rate
estimated at 85%, consent rate estimated at 60% and attri-
tion estimated at 15%, 600 participants will need to be
approached to achieve a sample of 260.
Study integrity
The study design and reporting will adhere to the
Consolidated Standards of Reporting Trials (CONSORT)
statement [48]. Usual care practice will be monitored
yearly with a questionnaire administered to nurses most
involved with the usual care of women with GC receiving
radiotherapy at each site. A consecutive sample will be
randomly allocated at the central site by computer with a
weighted-biased coin method 1:1 to either intervention or
usual care arms. Participants will be stratified according to
treating hospital and treatment type. Minimisation will be
used to balance the randomisation across the strata.
Participants will not be informed of their allocation
until the baseline questionnaire has been received. Blind-
ing of patients and providers to experimental arm can-
not be achieved with this study design, however
outcome assessment will be by self-reported question-
naire, thereby obviating the need for researcher blinding.
Usual care arm participants will receive a booklet on
their specific cancer diagnosis, treatment, and psycho-
sexual recovery to meet minimal ethical standards [49],
and information will be provided as per usual practice
by their treatment team. Reasons for attrition will be
recorded and recruitment and dropout bias assessed.
All nurse and peer sessions will be audio-taped and a
random sample of 15% of sessions will be assessed for
adherence to protocol. Length of sessions will be
reported. The first five calls or consultations made by
each peer and nurse will be reviewed and feedback pro-
vided on adherence to protocol, use of communication
and coaching skills and areas for improvement.Table 1 Time-points for collection of patient reported outcom
Time-point Questionnaire
Baseline & clinical exam I: (pre-treatment) Demographic and clin
(LENT SOMA scale)
Follow-up 1: (immediately prior to first radiotherapy) HADS, CaTS
Follow-up 2: (4 weeks post radiotherapy and post
intervention)
HADS, FACT-G, SCNS-S
Clinical exam II (3 months post radiotherapy) Clinical exam II (LENT
Follow-up 3 & clinical exam III:
(6 months post radiotherapy)
HADS, FACT-G, AQ, SV
Follow-up 4 & clinical exam IV:
(12 months post radiotherapy)
HADS, FACT-G, AQ, SV
AQ, Adherence questionnaire; CaTS, Cancer Treatment Survey; FACT-G, Functional A
Depression Scale; LENT SOMA, Late Effects of Normal Tissues / Subjective-Objective
Form; SCNS-SF34-R, Supportive Care Needs Survey - short form, Revised response foMeasures
Patients will complete self-report, pen and paper mea-
sures. Clinical vaginal assessments will be completed by
the treating clinician. Table 1 presents when measures
will be administered.
Demographics and clinical variables
Demographic details will be recorded by the patient on
the baseline questionnaire and include age, postcode,
marital and education status, employment situation and
occupation, living arrangements, whether they have chil-
dren, sexual orientation, country of birth and first lan-
guage, menopausal status, and antidepressant or sedative
use. Clinical details of diagnosis, diagnosis date, disease
stage, Eastern Cooperative Oncology Group (ECOG) per-
formance status, histopathology grade, history of another
cancer, treatment for a past diagnosis, current treatment
type (external beam, brachytherapy, concurrent chemo-
therapy), prior treatments (surgery, chemotherapy),
involvement with hospital services and Charlson co-
morbidity index will be completed by the data manager on
a case record form.
Clinical examination
The treating clinician will conduct clinical vaginal exami-
nations. The LENT SOMA scale (Late Effects of Normal
Tissues / Subjective-Objective Management Analytic), ob-
jective criteria for vaginal/sexual dysfunction [50,51] will
be used to measure vaginal changes.Psychological distress
Psychological distress will be assessed with the 14-item
HADS total scale (HADS-T) [52]. Rasch analysis shows
that items comprising the HADS-T form a unidimen-
sional construct of psychological distress [53]. It has
demonstrated high internal consistency (alpha=0.82 to
0.90) in patient populations including cancer patientses and clinical outcomes for the PeNTAGOn study
ical variables, HADS, FACT-G, SCNS-SF34-R, MSAS-SF, SVQ, clinical exam I
F34-R, MSAS-SF, AQ, CaTS and Patient Care evaluation & Referrals
SOMA scale)
Q, clinical exam III (LENT SOMA scale)
Q, clinical exam IV (LENT SOMA scale)
ssessment for Cancer Therapy - General; HADS, Hospital Anxiety and
Management Analytic; MSAS-SF, Memorial Symptom Assessment Scale Short
rmat; SVQ, Sexual function-vaginal changes questionnaire.
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studies [56,57].
Cancer-specific quality of life
Cancer-specific quality of life will be assessed with the
27-item Functional Assessment for Cancer Therapy -
General (FACT-G). The FACT-G comprises four subscales
for specific quality of life domains: physical, social, emo-
tional and functional wellbeing. Scaling and unidimen-
sionality of subscales have been confirmed by factor and
Rasch analyses [58,59]. All subscales have demonstrated
high internal consistency (alpha=0.72 to 0.90), good con-
vergent (r>0.51), divergent (r<0.22) and discriminative val-
idity in cancer patients [45] and responsiveness in
psychosocial intervention studies [57,60].
Unmet supportive care needs
The 34-item Supportive Care Needs Survey-short form
with revised response format (SCNS-SF34-R) [61,62] cov-
ers unmet needs from five domains: psychological; health
system and information; physical and daily living; patient
care and support; and sexuality. All domain subscales have
high internal consistency (alpha≥0.87) and good divergent
and convergent validity [63]. Aranda, Schofield and collea-
gues found this scale to be responsive to change in a re-
cent RCT with cancer patients [64].
Symptom distress
The 32-item Memorial Symptom Assessment Scale
Short Form (MSAS-SF) [65] comprises three subscales
(physical, psychological and global distress) and a total
symptom distress scale. All scales have demonstrated
high internal consistency (alpha=0.76 to 0.87), good con-
vergent validity (r =−0.68 to −0.74), excellent discrimina-
tive validity based on known groups comparisons [65]
and sensitivity to change in a longitudinal setting [66].
Sexual function and vaginal changes
The 27-item Sexual function-vaginal changes Question-
naire (SVQ) [67], developed for gynaecological cancer,
comprises three scales for all patients (intimacy, sexual
interest and global sexual satisfaction) and two scales for
sexually active respondents (vaginal changes and sexual
functioning). All five scales have demonstrated high in-
ternal consistency (alpha =0.76 to 0.83) [68] and sensi-
tivity to change longitudinally [67].
Cancer treatment-related information and support needs
Schofield et al. developed a 25-item Cancer Treatment
Survey (CaTS) [69] which comprises two subscales for
specific information and support needs domains: sensory-
psychological concerns and procedural concerns. Both
subscales have demonstrated high internal consistency
(alpha>0.90) and good divergent validity (with HADS:r<0.26) [69]. Both were sensitive to change in a recent
RCT [29].
Adherence questionnaire and patient care evaluation
Adherence to use of vaginal dilator, moisturiser, lubricant
and pelvic floor exercises will be assessed with a purpose
designed Adherence questionnaire (AQ). Patients’ per-
ceived global rating of change in psychological distress from
baseline and experience of referrals from commencement
of treatment will be assessed with a patient care evaluation
questionnaire, also purpose designed.
Statistical analyses
All data will be analyzed through SPSS Windows Ver-
sion 20.0 (SPSS, Chicago, IL, USA). After inspection of
the data, the appropriateness of all methods described
below will be reviewed and revised if necessary.
Preliminary analysis
Descriptive statistics will be used to summarise baseline
data, compliance with questionnaires and reasons for
non-compliance by study arm. Parametric and non-
parametric tests of association and mean differences as
appropriate will be used to assess recruitment bias and
possible differential attrition for consenting participants.
Outcome analysis
Outcome analyses will be carried out by fitting linear
mixed models (LMM) to each outcome separately. In
this case, a sequence of two-level models including ran-
dom intercepts and slopes will be constructed for each
outcome following recommended procedures [70]. Fully
parameterised models will also include fixed effects for
time (linear and higher-order polynomials, as appropri-
ate), group, site plus all two-way and cross-level interac-
tions. LMM use all available data, which supports an
intention-to-treat approach, and adjusts variance esti-
mates for the correlation between repeated measure-
ments on the same participants. Potential confounders
(that is, patient characteristics such as age) will be
included as co-variates. These will be centred to facili-
tate accurate interpretation of results and will be
retained in the final models if they explain significant
variation in outcomes and improve the precision of the
estimates of the treatment effect.
Secondary descriptive and planned subgroup analysis
For descriptive purposes, observed data will be used to
calculate within- and between-groups changes in study
outcomes from first assessment to follow-ups as specified
in the study hypotheses. Effect sizes for between-groups
differences will be calculated using recommended proce-
dures [71]. Interpretation of changes in the primary out-
come will be facilitated by results from an analysis of
Schofield et al. Trials 2013, 14:39 Page 9 of 11
http://www.trialsjournal.com/content/14/1/39participants’ global ratings of change in psychological dis-
tress [72,73]. For the primary outcome, subgroup analysis
will be used to investigate whether the intervention effect
differs significantly between participants with and without
clinically significant distress at baseline.
Discussion
This study will examine the effectiveness of an innova-
tive, tailored, nurse and peer-support package for
women with GC. Drawing on best available evidence the
standardised intervention is designed to be patient-
centred, promote adherence to self-care, provide co-
ordinated care including timely multidisciplinary team
referrals, and increase access to supportive care for
women who are sick or living in a remote setting, via
the telephone. This novel program is innovative in sev-
eral ways. First, it systematically engages peers over the
treatment trajectory which is likely to reduce nursing
time. Second, peers are linked in with the health profes-
sional team to encourage adherence to professionally-
delivered information. Third, phone contact is adopted
post-treatment completion to support those geographic-
ally or medically isolated. Finally, Level 1 evidence on
preparing patients for threatening medical procedures is
applied to the radiotherapy context.
We will employ a methodologically rigorous design,
incorporating comprehensive selection, training, and
monitoring of peers and nurses to ensure the interven-
tion is feasible in a real-world clinical setting. Should
this intervention be successful and widely disseminated,
it has the potential to reduce the physical, psychosexual,
and supportive care needs of women with GC. Addition-
ally, meeting patients’ psychological and supportive care
needs could have economic benefits as psychological
morbidity can result in greater healthcare use [74]. In
this new era which recognises consumers have an essen-
tial role in healthcare planning and delivery, the pro-
posed research program has the potential to transform
healthcare practices on an international level.
Trial status
Patient recruitment is open.
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